Skip to main content
Springer Nature Link
Log in

Comment on: “Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection Under Different Treatment Policies in Malaysia, 2018–2040”

  • Letter to the Editor
  • Published:
Applied Health Economics and Health Policy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. McDonald SA, Azzeri A, Shabaruddin FH, Dahlui M, Tan SS, Kamarulzaman A, et al. Projections of the healthcare costs and disease burden due to hepatitis C infection under different treatment policies in Malaysia, 2018–2040. Appl Health Econ Health Policy. 2018;16(6):847–57.

    Article  Google Scholar 

  2. McDonald SA, Mohamed R, Dahlui M, Naning H, Kamarulzaman A. Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis. BMC Infect Dis. 2014;14:564.

    Article  Google Scholar 

  3. The Ministry of Health, Malaysia. National strategic plan for hepatitis B and C 2019–2023. 2019. Available from: http://www.moh.gov.my/moh/resources/Penerbitan/Pelan%20Strategik%20/NSP_Hep_BC_2019_2023.pdf. Accessed 01 Nov 2019.

  4. Raihan R. Hepatitis in Malaysia: past, present, and future. Euroasian J Hepatogastroenterol. 2016;6(1):52–5.

    PubMed  PubMed Central  Google Scholar 

  5. Douglass CH, Pedrana A, Lazarus JV, Hoen EFM, Hammad R, Leite RB, et al. Pathways to ensure universal and affordable access to hepatitis C treatment. BMC Med. 2018;16(1):175.

    Article  Google Scholar 

  6. Drugs for neglected diseases initiative. Portfolio (ravisdavir + sofosbuvir). 2019. Available from: https://www.dndi.org/diseases-projects/portfolio/ravidasvir-sofosbuvir/. Accessed 01 Nov 2019.

  7. Drugs for neglected diseases initiative. FIND and DNDi team up to support Malaysian MOH efforts to simplify and decentralize hepatitis C screening and treatment. Available from: https://www.dndi.org/2018/media-centre/press-releases/find-dndi-malaysianmoh-efforts-hepatitisc-screening-treatment/. Accessed 01 Nov 2019.

  8. Drugs for neglected diseases initiative. Nationwide hepatitis C screening campaign initiated by the Malaysian Ministry of Health. Available from: https://www.dndi.org/2019/media-centre/press-releases/nationwide-hepatitisc-screening-campaign-malaysian-ministry-of-health/. Accessed 01 Nov 2019.

  9. Thomas S, Beh L, Nordin RB. Health care delivery in Malaysia: changes, challenges and champions. J Public Health Afr. 2011;2(2):e23.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology Unit, Department of Medicine, Sultanah Bahiyah Hospital, Ministry of Health, Alor Setar, Kedah, Malaysia

    Muhammad Radzi Abu Hassan

  2. Clinical Research Center, Sultanah Bahiyah Hospital, Ministry of Health, Alor Setar, Kedah, Malaysia

    Huan-Keat Chan

Authors
  1. Muhammad Radzi Abu Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huan-Keat Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muhammad Radzi Abu Hassan.

Ethics declarations

Funding

This is a self-funded letter.

Conflict of Interest

Muhammad Radzi Abu Hassan and Huan-Keat Chan have no conflicts of interest that are directly relevant to the content of this letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hassan, M.R.A., Chan, HK. Comment on: “Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection Under Different Treatment Policies in Malaysia, 2018–2040”. Appl Health Econ Health Policy 18, 139–140 (2020). https://doi.org/10.1007/s40258-019-00543-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40258-019-00543-x

Search

Navigation